Moreover, abnormal overproduction of A-FABP plays a critical role in obesity-related CVDs and endothelial dysfunction by increasing the accumulation of cholesterol and triglyceride and enhancing inflammation; together, this results in insulin resistance, atherosclerosis, and impaired activation of endothelial nitric oxide synthase (eNOS) [19]. Here, FABP4 is linked to obesity disorder.